Day: August 26, 2022

DUBLIN, Aug. 26, 2022 (GLOBE NEWSWIRE) — Kanine Pets World Limited, a subsidiary of Kanine Group, launches today (International Dog Day) on www.kanine.com products for dogs, which will include apparel (hoodies, padded jackets, bomber jackets, sweaters, polo shirts etc), accessories (collars, leashes and harnesses, bags), home products (beds, bowls, mats, travel bags etc) and toys for the brands BOSS Dog Accessories, DC League of Super-Pets and its own brand Kanine with many more international brands to follow.

“We’re so excited to launch kanine.com and to redefine the ecosphere of premium pet products for pawrents and their furbies. Kanine’s journey to bring something to everyone starts today with premium fashion such as BOSS Dog Accessories, superhero power such as DC League of Super-Pets and our own collection of Kanine products. This is only the beginning and we have a very strong pipeline of new and exciting brands and products to come. We’re very much looking forward to expanding the Kanine ecosphere,” says Samuel Wong, CEO and CFO, Kanine Group.

“It’s so amazing to launch Kanine.com, which will be the go-to place for dogs’ premium fashion and lifestyle products. I’ve worked with many of our partners on their adult and kids lines before and it’s amazing to now be able to add pets to the family! Our own Kanine brand is the quintessential ‘mini me’ brand for dogs so you can dress your pups in the same fashion colours and styles you wear yourself,” stated Sean Coxall, CMO, Kanine Group.

BOSS Dog Accessories launches with its first Fall Winter 2022 collection with a premium collection of fashionable dog apparel that ties with the BOSS adult wear designs and colours. The products are available worldwide in the online stores hugoboss.com and kanine.com, as well as in selected BOSS Stores, department stores and pet stores.

The “DC League of Super-Pets” range launches with Warner Bros. Pictures releasing the film in theaters only. The products are available in the greater Asia region on kanine.com, as well as in selected department stores and pet stores.

The Kanine range is a collection of fashionable dog apparel and accessories that have a preppy feel based on primary colours that match consumers’ lifestyle, enabling their dogs to have the same ‘mini me’ look as them. The collection of accessories such as collars, harnesses, and leads cater to small to large dogs with a versatile yet stylish look.

About Kanine Group:

Kanine Group designs, sources, and globally distributes pet apparel and accessories under various owned and licensed brands, including its namesake Kanine brand, and operates www.kanine.com, an exclusive platform for premium and exciting products, including apparel, accessories and home products for pets. Follow Kanine on Facebook, Instagram, Twitter and LinkedIn.

If you have any questions, please contact:

Sean Coxall

Chief Marketing Officer

E-mail: sean@kanine.com

WEBSITE : https://www.kanine.com

LINKEDIN: KANINE-INT

INSTAGRAM: BRAND_KANINE

FACEBOOK: BRANDKANINE

TWITTER: BRAND_KANINE

Related Files

Kanine Launch announcement Aug 26 copy.pdf

Related Images

Image 1: Kanine Brand

Kanine Brand Sweater

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Kanine Brand

August 26, 2022

Philips AI-powered interventional and diagnostic smart systems and at-home solutions connect care across the cardiology care pathway to enhance diagnostic confidence, drive greater efficiency, and improve patient outcomes

Amsterdam, the Netherlands and Barcelona, Spain – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest integrated cardiology solutions at the European Society of Cardiology (ESC) Congress (August 26-29, Barcelona, Spain). The company’s newest innovations in cardiology help provide enhanced clinical insights, strengthen clinical confidence, drive efficiency in critical care and improve cardiac care experiences from diagnosis and treatment to home care.

The demands on cardiology departments have never been higher, driving clinicians to balance the delivery of high-quality care for a growing volume of complex patients with pressures to improve departmental efficiency. The Future Health Index 2022 global report commissioned by Philips shows cardiology leaders not only see technology infrastructure improvements as key to managing and monitoring patients over extended periods of time in out-of-hospital settings, but also key to better diagnosing and treating the rising demand of new patients.

“As health systems navigate increased demand for cardiology services and complexity of patients, they face an ongoing challenge to provide quality patient care while adjusting to an increased focus on outcomes, efficiency, and costs,” said Dr. Alexandra Goncalves, Chief Medical Officer, Precision Diagnosis at Philips. “With our innovation in cardiology, Philips is uniquely positioned to deliver definitive diagnostics and enable personalized patient management to help improve cardiac care with greater efficiency, enhanced clinical insights and better experiences for patients and staff.”

Powerful ecosystem for cardiovascular care
Philips software-defined systems deliver data-driven insights, supported by AI, to provide the right care at the right time to help better manage even the most complex cardiology cases. Smart integrated end-to-end technology streamlines communication between devices and systems to help identify and address clinical as well as operational improvements, strengthen clinical confidence, build workflow efficiency, optimize resources and help lower the cost of care. Visitors to the Philips booth at ESC will see how the company is transforming cardiac care delivery into a connected future by integrating imaging, devices, software, informatics and services including:

• Precision diagnosis for cardiology – Clinically smart diagnostic solutions, streamlined workflows and actionable insights for data-driven cardiac care identify clear pathways for the most complex patient journeys. Advanced visualization solutions include Philips vendor-neutral, multi-modality image and information management workspace  – IntelliSpace Cardiovascular – and its new echocardiography viewing, analysis and reporting workspace (Ultrasound Workspace), a scalable solution making its debut in the European market at ESC, that when combined with Philips Ultrasound System (EPIQ CVx), leverages AI across a wide range of applications to provide advanced quantification and standardization with consistent on and off-cart applications. Together, these echocardiology workflow solutions help improve diagnostic confidence, enhance outcomes and operational effectiveness. Philips has also expanded access to hemodynamics at point of care for real-time blood flow assessment on its Lumify Handheld Ultrasound. In addition, Philips will spotlight its award-winning Spectral CT 7500 for exceptional cardiac imaging for a full cardiac assessment to help improve cardiac treatment pathways, and its cardiac MR portfolio of solutions including the helium-free MR 5300, Smart Workflow and AI-powered SmartSpeed, also debuting in Europe at ESC.
• Minimally-invasive treatment – Philips solutions for image-guided minimally invasive therapy help physicians to decide, guide, treat and confirm the right care for every cardiac patient in real time. Built on Philips Image-Guided Therapy System – Azurion – the company’s next generation image-guided therapy platform, these solutions uniquely integrate best in class imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment for the most complex procedures. At ESC, Philips will demonstrate how its innovative EchoNavigator software enables users of its EPIQ CVxi interventional cardiology ultrasound system to automatically fuse real-time 3D TEE (transesophageal echocardiography) with cardiac fluoroscopy X-ray imaging to monitor and assist catheter-based cardiac operations. Also featured is Coronary Suite, a fully integrated system for confident decision-making to help improve cardiac cath lab performance during percutaneous coronary intervention (PCI) procedures, and hemodynamic workflow for continuous monitoring, seamless data flow and continuity for cath lab patients.
• Ambulatory monitoring & diagnostics – Philips’ portfolio of remote cardiac care solutions includes near real-time patient monitoring, telehealth, emergency and therapeutic care, and cardiac ambulatory diagnostics and monitoring solutions to provide confident care across post-acute settings for chronic disease and readmission management. Solutions, which help to enable smooth transitions from the hospital to the home, include the Philips Extended Holter – ePatch for up to 14 days of continuous, high-quality ECG recording for reliable diagnosis [1], with robust data analysis provided by cloud-based, AI-enabled Philips Cardiologs software. A recent Cardiologs study demonstrated how AI may soon predict occurrence of atrial fibrillation. Also featured at ESC is Philips Questionnaire Manager, a cloud-based SaaS solution to better manage patient reported outcomes, and Philips Care Engagement Manager, helping empower clinicians to provide the right care at the right time, in the right place, while also engaging cardiac patients to take a more active role in their at-home recovery.

Philips’ hosted cardiac ultrasound symposium session at ESC 2022
As cardiology leaders look ahead to what’s next in diagnosing and treating heart failure, Philips will host a Cardiac Ultrasound Satellite Symposium session at ESC – Echo in heart failure, what can we do better now?  – Friday, August 26 at 3:30pm CET, and streamed live for those who are not attending ESC in person. The session will feature international thought leaders across the Netherlands, Italy and Spain who will share their insights on horizons in structural heart disease, the reality of using 3D for routine heart failure patients, and clinical experience with the fusion revolution. Visit Philips at ESC for more information.

Visit Philips Cardiology to learn how the company’s integrated systems, devices, informatics, software and services help deliver quick, confident diagnosis and effective treatment to improve outcomes for cardiovascular disease patients. Join Philips at ESC (Hall 3, Booth #K155) to hear how its data-driven, AI-powered smart systems and solutions help strengthen clinical confidence, streamline cardiac imaging workflows and improve the cardiac care experience for patients and staff.

[1] Patient will need to replace patch on day 5 of wear, or sooner as required.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978 221 8919
E-mail: Kathy.OReilly@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Clinicians using Ultrasound Workspace
• A clinician using Ultrasound Workspace
• Philips SmartSpeed MR software image

— the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA

SHANGHAI, China, Aug. 25, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that Suzhou Junjing Biomedical Technology Co., Ltd., a company jointly invested by Junshi Biosciences and Wigen Biomedicine Technology (Shanghai) Co., Ltd., has received a notice from the U.S. Food and Drug Administration (the “FDA”) concerning the approval of the investigational new drug (“IND”) application for XPO1 inhibitor WJ01024 tablets (product code: “JS110”) by the FDA. So far, 6 innovative drugs in Junshi Biosciences’ pipeline have obtained IND approval from the FDA, and with this newest addition, there are now 7.

About JS110
JS110 is a small molecule inhibitor of the nuclear export protein XPO1, which is clinically intended for the treatment of patients with advanced tumors. According to the results of pre-clinical studies, JS110 specifically blocks the function of XPO1, inhibits the nuclear export of various tumor suppressor proteins including p53, and strengthens the functions of tumor suppressor proteins. In vitro, JS110 inhibits the growth and induces death of various tumor cells; in animal tumor models, JS110 monotherapy and combination therapy can both inhibit the growth of various blood and solid tumors. Due to its unique mechanism of action, the development of JS110 may potentially bring new treatment options to patients with advanced tumors.

In April 2021, the IND application for JS110 was approved by the National Medical Products Administration. At present, the Phase I clinical trial of JS110 is in progress in the People’s Republic of China (NCT04991129).

Junshi Biosciences currently owns the world-wide exclusive production rights, licensed production rights and sales rights for JS110.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. A Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 versus nirmatrelvir/ritonavir (“PAXLOVID”) for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 provided patients with a shorter median time to sustained clinical recovery, while achieving statistical superiority. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

VICTOR, N.Y., Aug. 25, 2022 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 2022 Barclays Global Consumer Staples Conference on Wednesday, September 7 in Boston, Mass. The presentation is scheduled to begin at 11:15 a.m. ET and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future.

A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable or non-GAAP financial measures, will also be available on the company’s investor relations website under the Financial History section. For anyone unable to participate in the webcast, a replay will be available on the company’s website through the close of business on October 7, 2022.

ABOUT CONSTELLATION BRANDS

At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, our fine wine and craft spirits brands, including The Prisoner Wine Company, Robert Mondavi Winery, Casa Noble Tequila, and High West Whiskey, and our premium wine brands such as Meiomi, and Kim Crawford.

But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

To learn more, visit www.cbrands.com and follow us on Twitter, Instagram, and LinkedIn.

MEDIA CONTACTS	INVESTOR RELATIONS CONTACTS
Mike McGrew 773-251-4934 / michael.mcgrew@cbrands.com Amy Martin 585-678-7141 / amy.martin@cbrands.com	Joseph Suarez 773-551-4397 / joseph.suarez@cbrands.com

A downloadable PDF copy of this news release can be found here. http://ml.globenewswire.com/Resource/Download/654aee05-0a31-4958-835c-188e31ee1d29